Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies
Pharmacological Research · 2026
DOI: 10.1016/j.phrs.2026.108441 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2026. Verfasst von Pengfei Wen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Joint Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, PR China. Electronic address: wenpengfei@pku.edu.cn. Hauptthemen laut MEDLINE: Mitochondria, Musculoskeletal Diseases. Die Arbeit nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Musculoskeletal disorders (MSDs), including osteoporosis (OP), osteoarthritis (OA), and rheumatoid arthritis (RA), represent a stubborn burden in modern medicine. They share a breakdown in mitochondrial homeostasis. Mitochondrial dysfunction serves as a central pathogenic mechanism unifying these conditions and driving a paradigm shift from symptomatic management to mechanism-based therapeutic strategies. In this review, we examine how mitochondrial defects affect key cell types in bone, cartilage, and muscle, including osteoblasts, osteocytes, osteoclasts, chondrocytes, and skeletal muscle cells, with a focus on osteoporosis (OP), osteoarthritis (OA), and rheumatoid arthritis (RA) as the three primary musculoskeletal conditions that share mitochondrial dysfunction as a unifying mechanism. Impaired energy production, altered dynamics, defective quality control, and redox imbalance each contribute to disease progression. These disturbances drive oxidative damage, metabolic reprogramming, impaired mitophagy, and the release of pro-inflammatory signals known as mtDAMPs. Importantly, such defects are not irreversible, we further synthesize the emerging landscape of mitochondria-targeted strategies. These include antioxidants like MitoQ and SkQ1, metabolic modulators such as metformin and NAD⁺ boosters, mitophagy inducers like urolithin A, fission inhibitors including Mdivi-1, senolytic agents, and even mitochondrial transplantation. We conclude by proposing a precision medicine framework that matches specific mitochondrial abnormalities with mechanism-based interventions. Drawing on recent preclinical and clinical evidence, this review positions mitochondrial crosstalk as a promising foundation for developing disease-modifying therapies in musculoskeletal medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Joint Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, PR China. Electronic address: wenpengfei@pku.edu.cn.
- Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, 210019, PR China; School of Environment, Education and Development, The University of Manchester, Manchester, M13 9PL, UK.
- Department of Joint Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, PR China. Electronic address: yangzhi@xiyi.edu.cn.
Zitieren
APA
Wen, P., Bai, Y., & Yang, Z. (2026). Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies. Pharmacological Research. https://doi.org/10.1016/j.phrs.2026.108441
Vancouver
Wen P, Bai Y, Yang Z. Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies. Pharmacological Research. 2026. doi:10.1016/j.phrs.2026.108441
BibTeX
@article{Wen2026,
author = {Wen, Pengfei and Bai, Yuqi and Yang, Zhi},
title = {Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies},
journal = {Pharmacological Research},
year = {2026},
doi = {10.1016/j.phrs.2026.108441}
}
EUVIMED